BACKGROUND: Post-transplant hepatitis B virus (HBV) reinfection is one of the major problems facing patients who undergo HBV-related liver transplantation (LT). We analyzed the clinical impact of serum hepatitis B core-related antigen (HBcrAg) on HBV reinfection in post-LT patients with HBV-related liver diseases. METHODS: Serum hepatitis B surface antigen (HBsAg), HBV DNA, and HBcrAg were measured over time in 32 post-LT patients. Twenty-one out of 32 patients had HCC at LT. The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed. RESULTS: Sixteen out of 32 patients (50 %) were positive for HBcrAg even though only six patients were thought to have experienced HBV reinfection based on reappearance of either HBV DNA or HBsAg during a median follow-up time of 75 months. Three of these six patients who became re-infected with HBV experienced HCC recurrence after LT. The HBV DNA reappearance rate was significantly higher in patients with HCC recurrence after LT (p < 0.001). Two HBV re-infected patients without HCC recurrence had HBs gene mutations G145R and G145A, respectively. Anti-HBs antibody development rate by HB vaccination was similar between HBcrAg-positive and negative patients (p = 0.325). CONCLUSIONS: HBV reinfection is more common than is usually considered based on conventional measurement of HBsAg and HBV DNA. HCC recurrence and mutations in the HBV S gene were associated with HBV reinfection after LT.
BACKGROUND: Post-transplant hepatitis B virus (HBV) reinfection is one of the major problems facing patients who undergo HBV-related liver transplantation (LT). We analyzed the clinical impact of serum hepatitis B core-related antigen (HBcrAg) on HBV reinfection in post-LT patients with HBV-related liver diseases. METHODS: Serum hepatitis B surface antigen (HBsAg), HBV DNA, and HBcrAg were measured over time in 32 post-LT patients. Twenty-one out of 32 patients had HCC at LT. The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed. RESULTS: Sixteen out of 32 patients (50 %) were positive for HBcrAg even though only six patients were thought to have experienced HBV reinfection based on reappearance of either HBV DNA or HBsAg during a median follow-up time of 75 months. Three of these six patients who became re-infected with HBV experienced HCC recurrence after LT. The HBV DNA reappearance rate was significantly higher in patients with HCC recurrence after LT (p < 0.001). Two HBV re-infected patients without HCC recurrence had HBs gene mutations G145R and G145A, respectively. Anti-HBs antibody development rate by HB vaccination was similar between HBcrAg-positive and negative patients (p = 0.325). CONCLUSIONS:HBV reinfection is more common than is usually considered based on conventional measurement of HBsAg and HBV DNA. HCC recurrence and mutations in the HBV S gene were associated with HBV reinfection after LT.
Authors: A Sánchez-Fueyo; A Rimola; L Grande; J Costa; A Mas; M Navasa; I Cirera; J M Sánchez-Tapias; J Rodés Journal: Hepatology Date: 2000-02 Impact factor: 17.425
Authors: James Fung; Cindy Cheung; See-Ching Chan; Man-Fung Yuen; Kenneth S H Chok; William Sharr; Wing-Chiu Dai; Albert C Y Chan; Tan-To Cheung; Simon Tsang; Banny Lam; Ching-Lung Lai; Chung-Mau Lo Journal: Gastroenterology Date: 2011-07-14 Impact factor: 22.682
Authors: N V Naoumov; A R Lopes; P Burra; L Caccamo; R M Iemmolo; R A de Man; M Bassendine; J G O'Grady; B C Portmann; G Anschuetz; C A Barrett; R Williams; M Atkins Journal: J Hepatol Date: 2001-06 Impact factor: 25.083
Authors: Danny Ka-Ho Wong; Man-Fung Yuen; Ronnie Tung-Ping Poon; John Chi-Hang Yuen; James Fung; Ching-Lung Lai Journal: J Hepatol Date: 2006-06-23 Impact factor: 25.083
Authors: Thomas Steinmüller; Daniel Seehofer; Nada Rayes; Andrea R Müller; Utz Settmacher; Sven Jonas; Ruth Neuhaus; Thomas Berg; Uwe Hopf; Peter Neuhaus Journal: Hepatology Date: 2002-06 Impact factor: 17.425
Authors: Lewis W Teperman; Fred Poordad; Natalie Bzowej; Paul Martin; Surakit Pungpapong; Thomas Schiano; John Flaherty; Phillip Dinh; Stephen Rossi; G Mani Subramanian; James Spivey Journal: Liver Transpl Date: 2013-04-09 Impact factor: 5.799
Authors: Maria V Konopleva; Maxim S Belenikin; Andrei V Shanko; Alexey I Bazhenov; Sergei A Kiryanov; Tatyana A Tupoleva; Maria V Sokolova; Alexander V Pronin; Tatyana A Semenenko; Anatoly P Suslov Journal: Diagnostics (Basel) Date: 2021-05-27